Why the study?
GLP-1 RAs and SGLT-2 inhibitors reduced cardiovascular events in recent trials, but the comparative effectiveness among these new antidiabetic drug classes remained unclear.
Do new antidiabetic drug classes (GLP-1 RAs, SGLT-2 inhibitors, DPP-4 inhibitors) improve cardiovascular outcomes in patients with type 2 diabetes mellitus?
Comparison
GLP-1 RAs vs SGLT-2 inhibitors vs DPP-4 inhibitors vs placebo
Design
Network meta-analysis
Authors
Loading...
Supports SGLT-2 inhibitors and GLP-1 RAs for MACE reduction in T2DM; confirms SGLT-2 superiority for HF hospitalization in network meta-analysis.
Do new antidiabetic drug classes (GLP-1 RAs, SGLT-2 inhibitors, DPP-4 inhibitors) improve cardiovascular outcomes in patients with type 2 diabetes mellitus?
In a network meta-analysis, SGLT-2 inhibitors showed superiority in reducing cardiovascular deaths, heart failure hospitalizations, and renal events among new antidiabetic drug classes.
Fei et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: